Results 161 to 170 of about 749,314 (382)
Advanced Science, EarlyView.Enhancer eccANKRD28‐manipulated MM cells have been demonstrated to facilitate drug resistance and promote MM progression by activating the key transcription factor, POU2F2. POU2F2 interacts with sequence‐specific eccANKRD28 as well as RUNX1 and RUNX2 motifs to form the protein complex, which activates the promoter of oncogenes (IRF4, JUNB, IKZF3, et al.
Binzhen Chen +12 more
wiley +1 more source
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling
Haematologica, 2009 We examined the gene expression profiles of two independent cohorts of patients with acute myeloid leukemia [n=247 and n=214 (younger than or equal to 60 years)] to study the applicability of gene expression profiling as a single assay in prediction of ...
Roel G.W. Verhaak +8 more
doaj +1 more source
Identification and Counting White Blood Cells and Red Blood Cells using Image Processing Case Study of Leukemia [PDF]
arXiv, 2015 Leukemia is diagnosed with complete blood counts which is by calculating all blood cells and compare the number of white blood cells (White Blood Cells / WBC) and red blood cells (Red Blood Cells / RBC). Information obtained from a complete blood count, has become a cornerstone in the hematology laboratory for diagnostic purposes and monitoring of ...
arxiv
Nature Communications, 2018 Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 ...
A. Tron +36 more
semanticscholar +1 more source
STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
Advanced Science, EarlyView.STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken +3 more
wiley +1 more source
Molecular and cellular paradigms of multidrug resistance in cancer
Cancer Reports, Volume 5, Issue 12, December 2022., 2022 Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya +6 more
wiley +1 more source
Tumor Biology, 2019 Aurora kinases play critical roles in regulating several processes pivotal for mitosis. Radotinib, which is approved in South Korea as a second-line treatment for chronic myeloid leukemia, inhibits the tyrosine kinase BCR-ABL and platelet-derived growth ...
Sook-Kyoung Heo +10 more
doaj +1 more source
Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
Hematology Reports, 2014 Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for ...
Harry Ross Powers +4 more
doaj +1 more source
Automated Immunophenotyping Assessment for Diagnosing Childhood Acute Leukemia using Set-Transformers [PDF]
arXivAcute Leukemia is the most common hematologic malignancy in children and adolescents. A key methodology in the diagnostic evaluation of this malignancy is immunophenotyping based on Multiparameter Flow Cytometry (FCM). However, this approach is manual, and thus time-consuming and subjective. To alleviate this situation, we propose in this paper the FCM-
arxiv
Frequency of JAK2V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan [PDF]
, 1969 Najia Tabassum Mahfooz +3 more
openalex +1 more source